Cancer Cell
Papers 3218
1 page of 322 pages (3,218 results)
#1Ana Stojanovic (Heidelberg University)H-Index: 5
#2Adelheid Cerwenka (Heidelberg University)H-Index: 54
Discrete tissue niches are emerging as essential prerequisites enabling cell communication and function in both homeostasis and disease. In a recent Cell paper, Di Pilato et al. identify a unique dendritic cell-cytotoxic T cell crosstalk within the perivascular space that facilitates T cell survival and proliferation and drives anti-tumor activity.
#1Yubao Wang (Harvard University)H-Index: 12
#2Cherubin Manokaran (Harvard University)
Last. Thomas M. Roberts (Harvard University)H-Index: 107
view all 0 authors...
Cyclin-dependent kinase 7 (CDK7) is implicated in regulating the expression of cancer-dependent genes, and multiple CDK7-targeted therapies are currently under clinical investigation. Three recent studies elucidate the structure of human transcription machinery, offering vital mechanistic insights into CDK7 function and a potential pharmacodynamic marker of CDK7 activity in tumors.
#1Vivien Veninga (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
#2Emile Voest (NKI-AVL: Netherlands Cancer Institute)H-Index: 8
Summary null Tumor organoids have been proposed as a model system for precision medicine. The ability of tumor organoids to retain characteristics of the original tumor makes them unique for cancer research on an individual patient level. Hence, the idea to use tumor organoids for clinical decision making and optimize patient outcome is tempting. In vitro responses of tumor organoids to a wide array of drugs have been positively correlated to patient responses. However, substantial challenges re...
#1Yujue Wang (UCLA: University of California, Los Angeles)
#2Sixue Liu (UCLA: University of California, Los Angeles)H-Index: 2
view all 0 authors...
Summary null null Rationally sequencing and combining PD-1/L1-and MAPK-targeted therapies may overcome innate and acquired resistance. Since increased clinical benefit of MAPK inhibitors (MAPKi) is associated with previous immune checkpoint therapy, we compare the efficacies of sequential and/or combinatorial regimens in subcutaneous murine models of melanoma driven by BrafV600, Nras, or Nf1 mutations as well as colorectal and pancreatic carcinoma driven by KrasG12C. Anti-PD-1/L1 lead-in precedi...
#1Mario Mairhofer (Johannes Kepler University of Linz)
#2Lea Kausche (Johannes Kepler University of Linz)
view all 0 authors...
#1Lei Shen (SJTU: Shanghai Jiao Tong University)H-Index: 1
#2Youqiong Ye (SJTU: Shanghai Jiao Tong University)H-Index: 17
Last. Bing Su (SJTU: Shanghai Jiao Tong University)H-Index: 52
view all 0 authors...
The precise role of intestinal ILC3s in cancer remains largely unknown. Published in Cell, Goc et al. describe ILC3 function and plasticity in tumors. ILC3s may lose their identity and thus become either ILC1s or exhausting-ILC3s, which could in turn reshape the gut microbiome for colorectal cancer progression and immunotherapy resistance.
#1Xiuning Le (University of Texas MD Anderson Cancer Center)H-Index: 19
#2Monique B. Nilsson (University of Texas MD Anderson Cancer Center)H-Index: 23
Last. John V. Heymach (University of Texas MD Anderson Cancer Center)H-Index: 97
view all 4 authors...
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations.
#1Qing Zhou (Peking Union Medical College)H-Index: 29
#2Chong-Rui Xu (Peking Union Medical College)H-Index: 17
Last. Shun Lu (SJTU: Shanghai Jiao Tong University)H-Index: 32
view all 20 authors...
Dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways may delay therapeutic resistance in advanced non-small cell lung cancer (NSCLC). This phase 3 study investigated the efficacy and safety of an erlotinib plus bevacizumab regimen in untreated patients with advanced NSCLC. In total, 311 patients received bevacizumab plus erlotinib (n = 157) or erlotinib only (n = 154). Progression-free survival (PFS) was 17.9 months (95% confidence int...
1 CitationsSource
#1Kosuke Tanaka (MSK: Memorial Sloan Kettering Cancer Center)
#2Helena A. Yu (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 32
Last. Sonali Sinha (MSK: Memorial Sloan Kettering Cancer Center)
view all 20 authors...
Summary null The clinical success of EGFR inhibitors in EGFR-mutant lung cancer is limited by the eventual development of acquired resistance. We hypothesize that enhancing apoptosis through combination therapies can eradicate cancer cells and reduce the emergence of drug-tolerant persisters. Through high-throughput screening of a custom library of ∼1,000 compounds, we discover Aurora B kinase inhibitors as potent enhancers of osimertinib-induced apoptosis. Mechanistically, Aurora B inhibition s...
#1Bárbara da Silva (Cornell University)
#2Howard A. Fine (Cornell University)H-Index: 86
In a recent issue of Nature, Pan and colleagues explore whether light-induced stimulation of the optic nerve could influence the biology of optic gliomas. This study highlights the importance of neuronal-glioma interactions.
Top fields of study
Cancer research
Cell biology
Cancer cell